Evolent Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on September 1, 2022, covering events occurring on September 1, 2022, and September 6, 2022. The filing addresses significant changes in corporate leadership and board composition.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and governance matters.
Material Changes
- Executive Appointment: Dan McCarthy was named President of the Company, effective September 15, 2022. He will continue to serve as CEO of New Century Health, a subsidiary.
- Compensation Adjustment: In connection with his promotion, Mr. McCarthy's annual base salary was increased to $460,000. He is eligible for a target bonus of up to 175% of his base compensation for the year ending December 31, 2022, and may receive stock incentive awards.
- Board Departure: Frank Williams announced his intent not to stand for re-election at the 2023 Annual Meeting. He will remain a director until that meeting. The Board stated this decision was not due to any disagreement regarding company operations or policies.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. Management commentary is limited to the rationale for the leadership changes and the Board's appreciation for Mr. Williams' service.
Key Facts for Investor Verification
- Verify the effective date of Dan McCarthy's new role as President (September 15, 2022).
- Confirm the specific terms of the short-term cash incentive plan and stock incentive awards granted to Mr. McCarthy.
- Monitor the Company's announcement regarding the nomination of a replacement director for Frank Williams prior to the 2023 Annual Meeting.